Complications of myeloma and its treatments

Guidelines for screening and management of late and long-term consequences of myeloma and its treatment. Snowden JA et al. Br J Haematol. 2017 Jan 20. doi: 10.1111/bjh.14514. [Epub ahead of print]. The magnitude of neurotoxicity in patients with multiple myeloma and the impact of dose modifications: results from the population-based PROFILES registry. Beijers AJ et al. Ann Hematol. 2017 Jan 23. doi: 10.1007/s00277-017-2927-8. [Epub ahead…

Current treatments

Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial. Durie BG et al. Lancet. 2016 Dec 22. pii: S0140-6736(16)31594-X. doi: 10.1016/S0140-6736(16)31594-X. [Epub ahead of print]. Lenalidomide and low-dose dexamethasone (Rd) versus bortezomib, melphalan, prednisone (VMP) in elderly newly…

Guidelines for screening and management of late and long-term consequences of myeloma and its treatment

These guidelines, produced by the British Society of Haematology (BSH) and the UK Myeloma Forum (UKMF), highlight the late and long-term effects of myeloma and its treatments, and summarise the national consensus for the screening and management of these effects.

Snowden et al. (2017) British Journal of Haematology

Diagnostic techniques and prognostic indicators

Risk stratification in myeloma by detection of circulating plasma cells prior to autologous stem cell transplantation in the novel agent era. Chakraborty R et al. Blood Cancer J. 2016 Dec 16;6(12):e512. doi: 10.1038/bcj.2016.117. A gene expression inflammatory signature specifically predicts multiple myeloma evolution and patients survival. Botta C et al. Blood Cancer J. 2016 Dec 16;6(12):e511. doi: 10.1038/bcj.2016.118. 68Ga-PSMA PET/CT Imaging in Multiple Myeloma. Sasikumar A et…

Biology and genetics

Proteomic profiling in plasma cell disorders: a feasibility study. Mailankody S et al. Leuk Lymphoma. 2016 Dec 2:1-3. [Epub ahead of print]. Tumor-associated macrophage-mediated survival of myeloma cells through STAT3 activation. De Beule N et al. J Pathol. 2016 Dec 15. doi: 10.1002/path.4860. [Epub ahead of print]. Pharmacokinetics of lenalidomide during high cut-off dialysis in a patient with multiple myeloma and renal failure. Dao K et…

General

Outcomes of multiple myeloma patients receiving bortezomib, lenalidomide, and carfilzomib. Berenson A et al. Ann Hematol. 2016 Dec 8. [Epub ahead of print]. Practical Considerations in Managing Relapsed Multiple Myeloma. Agarwal A et al. Clin Lymphoma Myeloma Leuk. 2016 Nov 23. pii: S2152-2650(16)30873-4. doi: 10.1016/j.clml.2016.11.010. [Epub ahead of print]. Effects of Stress Appraisal on the Quality of Life of Adult Patients with Multiple Myeloma and Their Primary Family…

Supportive treatments

Bismuth adjuvant ameliorates adverse effects of high-dose chemotherapy in patients with multiple myeloma and malignant lymphoma undergoing autologous stem cell transplantation: a randomised, double-blind, prospective pilot study. Hansen PB et al. Support Care Cancer. 2016 Dec 13. [Epub ahead of print]. Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy. Di Nisio M et al. Cochrane Database Syst Rev. 2016 Dec…

Complications of myeloma and its treatments

Second malignancies in the context of lenalidomide treatment: an analysis of 2732 myeloma patients enrolled to the Myeloma XI trial. Jones JR et al. Blood Cancer J. 2016 Dec 9;6(12):e506. doi: 10.1038/bcj.2016.114. Spectrum of Cerebrovascular Disease in Patients with Multiple Myeloma Undergoing Chemotherapy-Results of a Case Control Study. Hinduja A et al. PLoS One. 2016 Nov 30;11(11):e0166627. doi: 10.1371/journal.pone.0166627. eCollection 2016. Bullous skin lesions in a patient…